Drugs / Osocimab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03787368 | Jan 2019 → Sep 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04523220 | Aug 2020 → Dec 2021 | end stage renal failure, venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT03276143 | Sep 2017 → Aug 2018 | osteoarthritis, knee | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Osocimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04523220 ↗ |
| Known as | BAY1213790 | “Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end...” NCT04523220 ↗ |
| Action | Inhibit | “It works by binding to and blocking the activated form of clotting factor XI” NCT04523220 ↗1“Coagulation factor XI negative allosteric modulator” CHEMBL4297905 ↗ |
| Modality | Monoclonal antibody | “Osocimab is a human monoclonal antibody under development for the prevention of events caused by blood clots like heart attack, stroke and death due to heart or blood vessels diseases.” NCT04523220 ↗ |
| Route | Intravenous | “administered as intravenous infusion” NCT03276143 ↗ |
| Target | F11 | “Coagulation factor XI negative allosteric modulator” CHEMBL4297905 ↗ |